215175-83-0

Basic information

• Product Name: Methyl 2-(4’-Acetyl-2-fluoro-biphenyl-4-yl)-propionate
• Synonyms: 2-(4’-Acetyl-2-fluoro-biphenyl-4-yl)-propionic Acid Methyl Ester;4'-Acetyl-2-fluoro-a-methyl-[1,1'-biphenyl]-4-acetic Acid Methyl Ester;Methyl 2-(4’-Acetyl-2-fluoro-biphenyl-4-yl)-propionate;4'-Acetyl-2-fluoro-α-Methyl-[1,1'-biphenyl]-4-acetic Acid Methyl Ester;2-(4a€-Acetyl-2-fluoro-biphenyl-4-yl)-propionic Acid Methyl Ester
• CAS NO: 215175-83-0
• Molecular Formula: C₁₈H₁₇FO₃
• Molecular Weight: 300.327
• Product Categories: Aromatics;Intermediates
• Mol File: 215175-83-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 26-27°C
• Boiling Point: 394.7 °C at 760 mmHg
• Flash Point: 185.9 °C
• Appearance: /
• Density: 1.152 g/cm³
• Solubility: Chloroform, Dichloromethane, Ethyl Acetate
• CAS DataBase Reference: Methyl 2-(4’-Acetyl-2-fluoro-biphenyl-4-yl)-propionate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-(4’-Acetyl-2-fluoro-biphenyl-4-yl)-propionate(215175-83-0)
• EPA Substance Registry System: Methyl 2-(4’-Acetyl-2-fluoro-biphenyl-4-yl)-propionate(215175-83-0)

Safety Data

• Hazardous Substances Data: 215175-83-0(Hazardous Substances Data)

Usage

Description

Methyl 2-(4’-Acetyl-2-fluoro-biphenyl-4-yl)-propionate is a chemical compound characterized as a yellow solid. It is an intermediate in the synthesis process of the metabolite of Flurbiprofen, which is an anti-inflammatory drug commonly used for its analgesic properties.

Uses

Used in Pharmaceutical Industry:
Methyl 2-(4’-Acetyl-2-fluoro-biphenyl-4-yl)-propionate is used as a chemical intermediate for the synthesis of the metabolite of Flurbiprofen. This is significant because Flurbiprofen serves as an anti-inflammatory analgesic, making the compound valuable in the development of medications aimed at reducing inflammation and pain.

Upstream product

• 113544-38-0 methyl 2-(2-fluoro-4-biphenylyl)propionate 
• 75-36-5 acetyl chloride 
• 5104-49-4 fluorobiprofen 
• 321-60-8 2-fluorobiphenyl 

Downstream Products

• 1435359-89-9 4-{2'-fluoro-4'-[1-oxo-1-(3-(1,2,3,4-tetrahydroacridin-9-ylamino)propylamino)propan-2-yl]biphenyl-4-yloxy}butyl nitrate 
• 1435359-97-9 6-{2'-fluoro-4'-[1-oxo-1-(3-(1,2,3,4-tetrahydroacridin-9-ylamino)propylamino)propan-2-yl]biphenyl-4-yloxy}hexyl nitrate 
• 1435360-05-6 2-{2'-fluoro-4'-[1-oxo-1-(4-(1,2,3,4-tetrahydroacridin-9-ylamino)butylamino)propan-2-yl]biphenyl-4-yloxy}ethyl nitrate 
• 1435360-13-6 3-{2'-fluoro-4'-[1-oxo-1-(4-(1,2,3,4-tetrahydroacridin-9-ylamino)butylamino)propan-2-yl]biphenyl-4-yloxy}propyl nitrate 
• 1435360-21-6 4-{2'-fluoro-4'-[1-oxo-1-(4-(1,2,3,4-tetrahydroacridin-9-ylamino)butylamino)propan-2-yl]biphenyl-4-yloxy}butyl nitrate 
• 1435360-29-4 6-{2'-fluoro-4'-[1-oxo-1-(4-(1,2,3,4-tetrahydroacridin-9-ylamino)butylamino)propan-2-yl]biphenyl-4-yloxy}hexyl nitrate 
• 215175-84-1 methyl 2-(4′-acetoxy-2-fluoro-[1,1′-biphenyl]-4-yl)propanoate 
• 52807-12-2 2-(2-fluoro-4'-hydroxy-biphenyl-4-yl)-propionic acid 
• 1435359-41-3 2-{2'-fluoro-4'-[1-oxo-1-(2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethylamino)propan-2-yl]biphenyl-4-yloxy}ethyl nitrate 
• 1435359-49-1 3-{2'-fluoro-4'-[1-oxo-1-(2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethylamino)propan-2-yl]biphenyl-4-yloxy}propyl nitrate 
• 1435359-57-1 4-{2'-fluoro-4'-[1-oxo-1-(2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethylamino)propan-2-yl]biphenyl-4-yloxy}butyl nitrate 
• 1435359-65-1 6-{2'-fluoro-4'-[1-oxo-1-(2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethylamino)propan-2-yl]biphenyl-4-yloxy}hexyl nitrate 
• 1435359-73-1 2-{2'-fluoro-4'-[1-oxo-1-(3-(1,2,3,4-tetrahydroacridin-9-ylamino)propylamino)propan-2-yl]biphenyl-4-yloxy}ethyl nitrate 
• 1435359-81-1 3-{2'-fluoro-4'-[1-oxo-1-(3-(1,2,3,4-tetrahydroacridin-9-ylamino)propylamino)propan-2-yl]biphenyl-4-yloxy}propyl nitrate 

Relevant articles and documents

Discovery of 4′-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities

A series of 4′-OH flurbiprofen Mannich base derivatives were designed, synthesized and evaluated as potential multifunctional agents for the treatment of Alzheimer's disease. The biological screening results indicated that most of these derivatives exhibi

NO-donating tacrine derivatives as potential butyrylcholinesterase inhibitors with vasorelaxation activity

To search for potent anti-Alzheimer's disease (AD) agents with multifunctional effects, 12 NO-donating tacrine-flurbiprofen hybrid compounds (2a-l) were synthesized and biologically evaluated. It was found that all the new target compounds showed selective butyrylcholinesterase (BuChE) inhibitory activity in vitro comparable or higher than tacrine and the tacrine-flurbiprofen hybrid compounds 1a-c, and released moderate amount of NO in vitro. The kinetic study suggests that one of the most active and highest BuChE selective compounds 2d may not only compete with the substrate for the same catalytic active site (CAS) but also interact with a second binding site. Furthermore, 2d and 2l exhibited significant vascular relaxation effect, which is beneficial for the treatment of AD. All the results suggest that 2d and 2l might be promising lead compounds for further research.

Isoxazole derivatives

An isoxazole derivative represented by the formula: or a pharmaceutically acceptable salt thereof useful as a therapeutic drug for auto-immune diseases and inflammatory diseases.